3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Squamous Cell Carcinoma of Head and Neck
4
Nasopharyngeal Carcinoma
3
Melanoma
3
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vascular Complications
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor
1
Recurrence
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Oropharyngeal Neoplasms
1
Oligoprogressive
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Mouth Neoplasms
1
Meningeal Carcinomatosis
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Locally Advanced Rectal Cancer
1
Immune-Related Adverse Events
1
Glioma
1
Esophageal Squamous Cell Carcinoma
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Cancer Metastatic
1
Interventions
pembrolizumab
4
olaparib
3
atezolizumab
3
Cetuximab
3
Trastuzumab
2
Docetaxel
2
zimberelimab
1
tocilizumab
1
spartalizumab
1
ribociclib
1
pralsetinib
1
pertuzumab
1
pegylated granulocyte colony-stimulating factor
1
ipatasertib
1
inavolisib
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
encorafenib
1
dapagliflozin
1
cemiplimab
1
binimetinib
1
anlotinib
1
amivantamab
1
alectinib
1
adagrasib
1
Pemetrexed
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Solid Tumors
×
Immune Checkpoint Inhibitors
×
90 days
×
Clear all
No trials found.